Purchase Order 75D30124P19059

Award Date 5/31/24
Potential Completion Date 8/1/24
Potential Value $20K
Federal Agency
CDC Pittsburgh
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
San Diego, CA 92122, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed price purchase order contract awarded by the Centers for Disease Control and Prevention (CDC) to Illumina, Inc., a leading manufacturer of genetic sequencing and genomic analysis technologies. The $236,726.60 contract is for a service agreement to provide the CDC with Illumina's advanced sequencing instruments, reagents, consumables, and bioinformatics software. The contract does not have a set-aside designation and has an ultimate completion date of August 31, 2026....
This is a firm fixed-price purchase order contract awarded by the Centers for Disease Control and Prevention (CDC) to Illumina, Inc., a leading manufacturer of genetic sequencing and genomic analysis technologies. The contract is for the provision of Genomic Sequencing Kits with a ceiling value of $170,641.14 and a performance period ending on August 28, 2024. The contract does not utilize a set-aside designation. Illumina is the prime contractor and has been awarded multiple federal contracts...
This firm fixed-price purchase order contract was awarded by the Centers for Disease Control and Prevention (CDC) Office of Acquisition Services to Illumina, Inc., a for-profit manufacturer of sequencing and array-based genomic analysis solutions. The $98,094.00 contract is for the provision of laboratory equipment, with no set-aside designation. Based on Illumina's past federal contract work, the equipment is likely to include Next-Generation DNA sequencing systems, reagents, and related...
This is a firm fixed price purchase order contract awarded by the Centers for Disease Control and Prevention (CDC) to Illumina, Inc., a leading manufacturer of genetic sequencing and genomic analysis technologies. The contract, valued at $223,532.40, is for the maintenance and services of Illumina sequencing instruments. The contract has an ultimate completion date of April 4, 2025 and does not utilize any set-aside designations. Illumina, headquartered in San Diego, California, is a...
This is a firm fixed price purchase order contract awarded by the Centers for Disease Control and Prevention (CDC) Pittsburgh office to Illumina, Inc., a manufacturer of genetic sequencing systems and reagents. The contract, valued at $20,400.00, is for the provision of ILLUMINA - AMPLISEQ products and services, with a period of performance through September 30, 2024. The contract has no set-aside designation. Illumina has a history of providing sequencing equipment and consumables to support...
The Department of Health and Human Services Centers for Disease Control and Prevention (CDC) awarded a Firm Fixed Price purchase order to Illumina, Inc., a manufacturer of sequencing and genomic analysis solutions, for the provision of lab supplies. The $16,168.00 contract has an April 29, 2024 completion date and was awarded on August 22, 2019. The lab supplies are to be delivered to the CDC's location in Atlanta, GA. Illumina is a for-profit organization and manufacturer that has previously...
This firm fixed-price purchase order was awarded by the Centers for Disease Control and Prevention (CDC) to Illumina, Inc., a manufacturer of sequencing and array-based solutions for genetic and genomic analysis. The $85,056.40 contract is for the delivery of laboratory reagents, with an ultimate completion date of July 31, 2022. The contract does not have a set-aside designation. Illumina has previously received federal prime contract and subcontract awards from agencies like the National...
This is a firm fixed price purchase order contract awarded by the Centers for Disease Control and Prevention (CDC) to Illumina, Inc. for the supply of lab supplies. The contract has a ceiling value of $97,152 and runs through February 28, 2017. The contract is not set aside for any special business designation. Illumina is a manufacturer and provider of sequencing and array-based solutions for genetic and genomic analysis. Through past federal contract awards, Illumina has provided a range of...
The Department of Health and Human Services Centers for Disease Control and Prevention (CDC) awarded a firm fixed price purchase order contract to Illumina, Inc., a manufacturer of sequencing and array-based solutions for genetic and genomic analysis. The $22,376.85 contract is for the provision of an ISEQ 100 SYSTEM, with a completion date of March 1, 2026. This award does not have a set-aside designation. Illumina has previously received prime federal contracts from agencies such as the NIH,...
The Department of Health and Human Services (HHS) Centers for Disease Control and Prevention (CDC) awarded a firm fixed price purchase order to Illumina, Inc., a manufacturer of genomic sequencing instruments and reagents, for reagents to be used with Illumina's sequencing systems. The $219,192.00 contract does not have a set-aside designation and is intended to support the CDC's needs through August 31, 2022. Illumina has a history of providing sequencing equipment, consumables, and services to...

This firm fixed-price purchase order contract was awarded by the Centers for Disease Control and Prevention (CDC) to Illumina, Inc., a manufacturer of genetic sequencing instruments and reagents, to facilitate the relocation of equipment to accommodate COVID-19 (CORVD) operations. The $20,092.00 contract has an ultimate completion date of August 1, 2024. Illumina has a history of providing sequencing systems and associated services to support genomic research and diagnostics across various federal agencies. While the original solicitation is not provided, the contract aligns with the CDC's mission to protect public health and respond to emerging infectious diseases. No set-aside designation is noted. Illumina has also received federal contract and grant awards, as well as subcontracts, from other government entities for similar genomics-related products and services.

Generated 8/2/24, 9:15 AM